Michael B. Jameson - Concepedia

Author

Michael B. Jameson

Also Known As

Dec22, H. Tokunaga, Jameson, Michael (Stanford), M B Jameson, M Jameson, M. B. Jameson, M. Jameson, M.B. Jameson, MICHAEL B. JAMESON, Michael B Jameson

188

Publications

3.6K

Citations

H-Index

Concepts

All Affiliations

Waikato Hospital University of Auckland Auckland City Hospital Christchurch Hospital Chris O’Brien Lifehouse

About

Michael B. Jameson is an author at Waikato Hospital specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	24	1.5K
2	Public Health	2	2	33
3	Engineering	1	1	12
4	Health Sciences	1	1	32
5	Natural Sciences	1	1	31

Michael B. Jameson

Publications

2.9K

Citations

H-Index

Page 1

	Year	Citations
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial Alexander Eggermont, Christian U. Blank, Mario Mandalà, The Lancet Oncology Surgical OncologyMedicineMelanomaImmunologyImmune Checkpoint Inhibitor	2021	364
Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial Georgina V. Long, Victoria Atkinson, Jonathan Cebon, The Lancet Oncology Standard-dose PembrolizumabMedicineMelanomaClinical TrialsImmune Checkpoint Inhibitor	2017	246
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors Jayesh Desai, Sanjeev Deva, Jong Seok Lee, Journal for ImmunoTherapy of Cancer	2020	145
Effects of 5,6-Dimethylxanthenone-4-Acetic Acid on Human Tumor Microcirculation Assessed by Dynamic Contrast-Enhanced Magnetic Resonance Imaging Susan Galbraith, Gordon Rustin, Martin A. Lodge, Journal of Clinical Oncology	2002	144
Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent Michael B. Jameson, Paul Thompson, Bruce C. Baguley, British Journal of Cancer	2003	139
Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer Mark J. McKeage, Joachim von Pawel, Martin Reck, British Journal of Cancer	2008	125
Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid L‐M Ching, Z Cao, Claudine Kiéda, British Journal of Cancer	2002	122
Successful triage of patients referred to a skin lesion clinic using teledermoscopy (IMAGE IT trial) Eugene Tan, Anthony Yung, Michael B. Jameson, British Journal of Dermatology	2010	117
A Phase 1 Study of AS1409, a Novel Antibody-Cytokine Fusion Protein, in Patients with Malignant Melanoma or Renal Cell Carcinoma Sarah Maria Rudman, Michael B. Jameson, Mark J. McKeage, Clinical Cancer Research	2011	107
Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors Jayesh Desai, Hui Gan, Catherine Barrow, Journal of Clinical Oncology	2020	103

Page 1